429 related articles for article (PubMed ID: 24294922)
1. Ewing's sarcoma cancer stem cell targeted therapy.
Todorova R
Curr Stem Cell Res Ther; 2014 Jan; 9(1):46-62. PubMed ID: 24294922
[TBL] [Abstract][Full Text] [Related]
2. Overexpression of HOX genes is prevalent in Ewing sarcoma and is associated with altered epigenetic regulation of developmental transcription programs.
Svoboda LK; Harris A; Bailey NJ; Schwentner R; Tomazou E; von Levetzow C; Magnuson B; Ljungman M; Kovar H; Lawlor ER
Epigenetics; 2014 Dec; 9(12):1613-25. PubMed ID: 25625846
[TBL] [Abstract][Full Text] [Related]
3. Modeling initiation of Ewing sarcoma in human neural crest cells.
von Levetzow C; Jiang X; Gwye Y; von Levetzow G; Hung L; Cooper A; Hsu JH; Lawlor ER
PLoS One; 2011 Apr; 6(4):e19305. PubMed ID: 21559395
[TBL] [Abstract][Full Text] [Related]
4. EWS-FLI-1 expression triggers a Ewing's sarcoma initiation program in primary human mesenchymal stem cells.
Riggi N; Suvà ML; Suvà D; Cironi L; Provero P; Tercier S; Joseph JM; Stehle JC; Baumer K; Kindler V; Stamenkovic I
Cancer Res; 2008 Apr; 68(7):2176-85. PubMed ID: 18381423
[TBL] [Abstract][Full Text] [Related]
5. Ewing's sarcoma oncoprotein EWS-FLI1: the perfect target without a therapeutic agent.
Uren A; Toretsky JA
Future Oncol; 2005 Aug; 1(4):521-8. PubMed ID: 16556028
[TBL] [Abstract][Full Text] [Related]
6. Targeting the EWS-ETS transcriptional program by BET bromodomain inhibition in Ewing sarcoma.
Hensel T; Giorgi C; Schmidt O; Calzada-Wack J; Neff F; Buch T; Niggli FK; Schäfer BW; Burdach S; Richter GH
Oncotarget; 2016 Jan; 7(2):1451-63. PubMed ID: 26623725
[TBL] [Abstract][Full Text] [Related]
7. Blocking the road, stopping the engine or killing the driver? Advances in targeting EWS/FLI-1 fusion in Ewing sarcoma as novel therapy.
Kovar H
Expert Opin Ther Targets; 2014 Nov; 18(11):1315-28. PubMed ID: 25162919
[TBL] [Abstract][Full Text] [Related]
8. Targeting the epigenetic readers in Ewing sarcoma inhibits the oncogenic transcription factor EWS/Fli1.
Jacques C; Lamoureux F; Baud'huin M; Rodriguez Calleja L; Quillard T; Amiaud J; Tirode F; Rédini F; Bradner JE; Heymann D; Ory B
Oncotarget; 2016 Apr; 7(17):24125-40. PubMed ID: 27006472
[TBL] [Abstract][Full Text] [Related]
9. Impact of EWS-ETS fusion type on disease progression in Ewing's sarcoma/peripheral primitive neuroectodermal tumor: prospective results from the cooperative Euro-E.W.I.N.G. 99 trial.
Le Deley MC; Delattre O; Schaefer KL; Burchill SA; Koehler G; Hogendoorn PC; Lion T; Poremba C; Marandet J; Ballet S; Pierron G; Brownhill SC; Nesslböck M; Ranft A; Dirksen U; Oberlin O; Lewis IJ; Craft AW; Jürgens H; Kovar H
J Clin Oncol; 2010 Apr; 28(12):1982-8. PubMed ID: 20308673
[TBL] [Abstract][Full Text] [Related]
10. EWS-FLI-1 modulates miRNA145 and SOX2 expression to initiate mesenchymal stem cell reprogramming toward Ewing sarcoma cancer stem cells.
Riggi N; Suvà ML; De Vito C; Provero P; Stehle JC; Baumer K; Cironi L; Janiszewska M; Petricevic T; Suvà D; Tercier S; Joseph JM; Guillou L; Stamenkovic I
Genes Dev; 2010 May; 24(9):916-32. PubMed ID: 20382729
[TBL] [Abstract][Full Text] [Related]
11. Treatment of Ewing's sarcoma using an antisense oligodeoxynucleotide to regulate the cell cycle.
Asami S; Chin M; Shichino H; Yoshida Y; Nemoto N; Mugishima H; Suzuki T
Biol Pharm Bull; 2008 Mar; 31(3):391-4. PubMed ID: 18310898
[TBL] [Abstract][Full Text] [Related]
12. Absence of detectable EWS/FLI1 expression after therapy-induced neural differentiation in Ewing sarcoma.
Knezevich SR; Hendson G; Mathers JA; Carpenter B; Lopez-Terrada D; Brown KL; Sorensen PH
Hum Pathol; 1998 Mar; 29(3):289-94. PubMed ID: 9496833
[TBL] [Abstract][Full Text] [Related]
13. Potential approaches to the treatment of Ewing's sarcoma.
Yu H; Ge Y; Guo L; Huang L
Oncotarget; 2017 Jan; 8(3):5523-5539. PubMed ID: 27740934
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of SOX2 induces cell apoptosis and G1/S arrest in Ewing's sarcoma through the PI3K/Akt pathway.
Ren C; Ren T; Yang K; Wang S; Bao X; Zhang F; Guo W
J Exp Clin Cancer Res; 2016 Mar; 35():44. PubMed ID: 26969300
[TBL] [Abstract][Full Text] [Related]
15. Caveolin-1 (CAV1) is a target of EWS/FLI-1 and a key determinant of the oncogenic phenotype and tumorigenicity of Ewing's sarcoma cells.
Tirado OM; Mateo-Lozano S; Villar J; Dettin LE; Llort A; Gallego S; Ban J; Kovar H; Notario V
Cancer Res; 2006 Oct; 66(20):9937-47. PubMed ID: 17047056
[TBL] [Abstract][Full Text] [Related]
16. Molecular assessment of circulating exosomes toward liquid biopsy diagnosis of Ewing sarcoma family of tumors.
Zhang P; Samuel G; Crow J; Godwin AK; Zeng Y
Transl Res; 2018 Nov; 201():136-153. PubMed ID: 30031766
[TBL] [Abstract][Full Text] [Related]
17. EWS-FLI1 in Ewing's sarcoma: real targets and collateral damage.
Ban J; Siligan C; Kreppel M; Aryee D; Kovar H
Adv Exp Med Biol; 2006; 587():41-52. PubMed ID: 17163154
[TBL] [Abstract][Full Text] [Related]
18. RNA sequencing and functional studies of patient-derived cells reveal that neurexin-1 and regulators of this pathway are associated with poor outcomes in Ewing sarcoma.
Roundhill EA; Chicon-Bosch M; Jeys L; Parry M; Rankin KS; Droop A; Burchill SA
Cell Oncol (Dordr); 2021 Oct; 44(5):1065-1085. PubMed ID: 34403115
[TBL] [Abstract][Full Text] [Related]
19. Transactivation of cyclin E gene by EWS-Fli1 and antitumor effects of cyclin dependent kinase inhibitor on Ewing's family tumor cells.
Li X; Tanaka K; Nakatani F; Matsunobu T; Sakimura R; Hanada M; Okada T; Nakamura T; Iwamoto Y
Int J Cancer; 2005 Sep; 116(3):385-94. PubMed ID: 15818598
[TBL] [Abstract][Full Text] [Related]
20. Loss of connexin43 expression in Ewing's sarcoma cells favors the development of the primary tumor and the associated bone osteolysis.
Talbot J; Brion R; Picarda G; Amiaud J; Chesneau J; Bougras G; Stresing V; Tirode F; Heymann D; Redini F; Verrecchia F
Biochim Biophys Acta; 2013 Apr; 1832(4):553-64. PubMed ID: 23313578
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
